Peninsula biotech lands $55M as Big Pharma exercises option on Alzheimer’s drug

The move is validation of sorts for the South San Francisco company, whose predecessor a decade ago saw multiple clinical flops of its experimental Alzheimer’s drug.
Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks